Vesicular Polysaccharide Export in Cryptococcus neoformans Is a Eukaryotic Solution to the Problem of Fungal Trans-Cell Wall Transport

ABSTRACT The mechanisms by which macromolecules are transported through the cell wall of fungi are not known. A central question in the biology of Cryptococcus neoformans, the causative agent of cryptococcosis, is the mechanism by which capsular polysaccharide synthesized inside the cell is exported to the extracellular environment for capsule assembly and release. We demonstrate that C. neoformans produces extracellular vesicles during in vitro growth and animal infection. Vesicular compartments, which are transferred to the extracellular space by cell wall passage, contain glucuronoxylomannan (GXM), a component of the cryptococcal capsule, and key lipids, such as glucosylceramide and sterols. A correlation between GXM-containing vesicles and capsule expression was observed. The results imply a novel mechanism for the release of the major virulence factor of C. neoformans whereby polysaccharide packaged in lipid vesicles crosses the cell wall and the capsule network to reach the extracellular environment.

[1]  S. A. Meyer,et al.  Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans , 1991, Infection and immunity.

[2]  K. Takeo,et al.  Fine Structure of Cryptococcus neoformans Grown In Vivo as Observed by Freeze-Etching , 1973, Journal of bacteriology.

[3]  A. Casadevall,et al.  Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro , 1997, Infection and immunity.

[4]  A. Casadevall,et al.  Cryptococcus neoformans Is a Facultative Intracellular Pathogen in Murine Pulmonary Infection , 2000, Infection and Immunity.

[5]  A. Casadevall,et al.  The Physical Properties of the Capsular Polysaccharides from Cryptococcus neoformans Suggest Features for Capsule Construction* , 2006, Journal of Biological Chemistry.

[6]  J. Salamero,et al.  Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide , 1987, Infection and immunity.

[7]  P. Novikoff,et al.  Cytochemical contributions to differentiating GERL from the Golgi apparatus , 1977, The Histochemical Journal.

[8]  T. Baba,et al.  Ultrastructural study ofCryptococcus neoformans by quick-freezing and deep-etching method , 1993, Mycopathologia.

[9]  A. Casadevall,et al.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide. , 1992, Journal of immunological methods.

[10]  A. Casadevall,et al.  Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K. Kwon-Chung,et al.  Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence , 1994, Molecular and cellular biology.

[12]  A. Casadevall,et al.  Characterization of a Murine Monoclonal Antibody toCryptococcus neoformans Polysaccharide That Is a Candidate for Human Therapeutic Studies , 1998, Antimicrobial Agents and Chemotherapy.

[13]  T. Doering,et al.  A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis. , 2006, Molecular biology of the cell.

[14]  Y. Hannun,et al.  The Sphingolipid Pathway Regulates Pkc1 through the Formation of Diacylglycerol in Cryptococcus neoformans* , 2004, Journal of Biological Chemistry.

[15]  A. Casadevall,et al.  Experimental modulation of capsule size in Cryptococcus neoformans , 2004, Biological Procedures Online.

[16]  P. Altevogt,et al.  ADAM10‐mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  T. Scallen,et al.  Isolation and Characterization of C-4 Methyl Intermediates in Cholesterol Biosynthesis after Treatment of Rat Liver in Vitro with Cholestan-3β,5α,6β-triol , 1971 .

[18]  A. Casadevall,et al.  Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. , 2001, Microbiology.

[19]  K. Takeo,et al.  Fine Structure of Cryptococcus neoformans Grown In Vitro as Observed by Freeze-Etching , 1973, Journal of bacteriology.

[20]  L. Travassos,et al.  The multitude of targets for the immune system and drug therapy in the fungal cell wall. , 2005, Microbes and infection.

[21]  B. Thomma,et al.  Defensins from Insects and Plants Interact with Fungal Glucosylceramides* , 2004, Journal of Biological Chemistry.

[22]  J. Geibel,et al.  Direct observation of oxidative stress on the cell wall of Saccharomyces cerevisiae strains with atomic force microscopy , 1999, Molecular and Cellular Biochemistry.

[23]  A. Casadevall,et al.  Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis , 2005, Antimicrobial Agents and Chemotherapy.

[24]  M. Del Poeta,et al.  The Role and Mechanism of Diacylglycerol-Protein Kinase C1 Signaling in Melanogenesis by Cryptococcus neoformans* , 2005, Journal of Biological Chemistry.

[25]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[26]  Maria Teresa Montagna,et al.  APP1 Transcription Is Regulated by Inositol-phosphorylceramide Synthase 1-Diacylglycerol Pathway and Is Controlled by ATF2 Transcription Factor in Cryptococcus neoformans* , 2005, Journal of Biological Chemistry.

[27]  H. Riezman,et al.  Intracellular transport of GPI‐anchored proteins , 2000, The EMBO journal.

[28]  A. Casadevall,et al.  The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding , 2006, Molecular microbiology.

[29]  A. Casadevall,et al.  Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures. , 2005, Vaccine.

[30]  T. Doering,et al.  Specific requirements for the ER to Golgi transport of GPI-anchored proteins in yeast. , 1997, Journal of cell science.

[31]  I. Almeida,et al.  Structure, Cellular Distribution, Antigenicity, and Biological Functions of Fonsecaea pedrosoi Ceramide Monohexosides , 2005, Infection and Immunity.

[32]  P. Kuchel,et al.  Identification of extracellular phospholipase B, lysophospholipase, and acyltransferase produced by Cryptococcus neoformans , 1997, Infection and immunity.

[33]  M. Rodrigues,et al.  Structure and biological functions of fungal cerebrosides. , 2004, Anais da Academia Brasileira de Ciencias.

[34]  M. Hennig,et al.  Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans. , 2006, The Journal of clinical investigation.

[35]  A. Casadevall,et al.  Cryptococcus neoformans CAP59 (or Cap59p) Is Involved in the Extracellular Trafficking of Capsular Glucuronoxylomannan , 2004, Eukaryotic Cell.

[36]  L. Travassos,et al.  Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms. , 1999, Microbes and infection.

[37]  R. Prasad,et al.  Lipids of Pathogenic Fungi , 1996 .

[38]  W. de Souza,et al.  Human Antibodies against a Purified Glucosylceramide from Cryptococcus neoformans Inhibit Cell Budding and Fungal Growth , 2000, Infection and Immunity.

[39]  A. Vecchiarelli,et al.  Immunoregulation by capsular components of Cryptococcus neoformans. , 2000, Medical mycology.

[40]  T. Kozel.  Virulence factors of Cryptococcus neoformans. , 1995, Trends in microbiology.

[41]  N. Sakaguchi.  Ultrastructural study of hepatic granulomas induced byCryptococcus neoformans by quick-freezing and deep-etching method , 1993, Virchows Archiv. B, Cell pathology including molecular pathology.